Clinical Report: Perioperative Circulating Tumor Cells in Resectable Colorectal Cancer
Overview
This study evaluated perioperative circulating tumor cells (CTCs) in 81 colorectal cancer patients undergoing surgery, using microfluidic chip technology. Findings suggest that changes in CTC counts before and after surgery correlate with lymph node metastasis and may have prognostic value.
Background
Colorectal cancer (CRC) is a leading cause of cancer morbidity and mortality worldwide. Despite advances in treatment, recurrence and metastasis remain common, often due to occult dissemination of tumor cells. Circulating tumor cells (CTCs) are viable cancer cells shed into the bloodstream and represent a potential biomarker for real-time monitoring of tumor progression and metastasis. Current diagnostic methods lack sensitivity and real-time capability, highlighting the need for improved monitoring tools such as CTC detection.
Data Highlights
A total of 103 CRC patients were initially recruited; after exclusions, 81 patients had paired preoperative and postoperative blood samples analyzed for CTCs. Microfluidic chip technology was used for CTC isolation and quantification. The study focused on perioperative changes in CTC counts and their association with clinicopathological features, particularly lymph node metastasis.
Key Findings
CTCs were successfully isolated and quantified from peripheral blood samples before and after colorectal cancer surgery using microfluidic chip technology.
Perioperative variations in CTC counts were observed, with changes correlating to the presence of lymph node metastasis.
Dynamic monitoring of CTCs may provide earlier indication of tumor dissemination compared to conventional imaging and serum markers.
CTC counts could potentially stratify patients by risk and guide more personalized treatment plans.
The study supports the clinical utility of CTC detection as a minimally invasive, real-time biomarker for prognosis and treatment monitoring in CRC.
Clinical Implications
Monitoring perioperative CTC levels can enhance early detection of metastasis and recurrence risk in colorectal cancer patients. Incorporating CTC quantification into clinical practice may improve patient stratification and guide decisions on adjuvant therapy. This approach offers a minimally invasive method to complement existing diagnostic tools for more precise and dynamic disease management.
Conclusion
Perioperative changes in circulating tumor cells provide valuable prognostic information in resectable colorectal cancer. Microfluidic-based CTC detection represents a promising tool for real-time monitoring and personalized treatment strategies.
References
Global Cancer Statistics 2020 -- Colorectal Cancer Incidence and Mortality
Clinical Significance of Circulating Tumor Cells in CRC -- Prognosis and Monitoring
Microfluidic Technologies for CTC Isolation -- Advances and Applications
